Close
Help


INtegrative Platform for Cancer Transcriptomics

Posted Thu, Mar, 13,2014

Published today in Cancer Informatics is a new original research article by Piyush B. Madhamshettiwar, Stefan R. Maetschke, Melissa J. Davis, Antonio Reverter and Mark A. Ragan.  Read more about this paper below:

Title

INsPeCT: INtegrative Platform for Cancer Transcriptomics

Abstract

The emergence of transcriptomics, fuelled by high-throughput sequencing technologies, has changed the nature of cancer research and resulted in a massive accumulation of data. Computational analysis, integration, and data visualization are now major bottlenecks in cancer biology and translational research. Although many tools have been brought to bear on these problems, their use remains unnecessarily restricted to computational biologists, as many tools require scripting skills, data infrastructure, and powerful computational facilities. New user-friendly, integrative, and automated analytical approaches are required to make computational methods more generally useful to the research community. Here we present INsPeCT (INtegrative Platform for Cancer Transcriptomics), which allows users with basic computer skills to perform comprehensive in-silico analyses of microarray, ChIP-seq, and RNA-seq data. INsPeCT supports the selection of interesting genes for advanced functional analysis. Included in its automated workflows are (i) a novel analytical framework, RMaNI (regulatory module network inference), which supports the inference of cancer subtype-specific transcriptional module networks and the analysis of modules; and (ii) WGCNA (weighted gene co-expression network analysis), which infers modules of highly correlated genes across microarray samples, associated with sample traits, eg survival time. INsPeCT is available free of cost from Bioinformatics Resource Australia-EMBL and can be accessed at http://inspect.braembl.org.au.

Click here to learn more about the article, download it and comment

share on

Posted in: Articles Published

  • Efficient Processing: 4 Weeks Average to First Editorial Decision
  • Fair & Independent Expert Peer Review
  • High Visibility & Extensive Database Coverage
Services for Authors
What Your Colleagues Say About Libertas Academica
The editorial staff of Biomarkers in Cancer are very efficient and helpful.  I am happy to work with them.  I look forward to reviewing future manuscripts.
Dr Xi Liu (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA )
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube